MARKET

EYPT

EYPT

EyePoint Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
+0.030
+2.04%
After Hours: 1.510 +0.01 +0.67% 16:05 12/06 EST
OPEN
1.470
PREV CLOSE
1.470
HIGH
1.510
LOW
1.465
VOLUME
507.83K
TURNOVER
--
52 WEEK HIGH
2.824
52 WEEK LOW
1.190
MARKET CAP
162.18M
P/E (TTM)
-2.6920
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EYPT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EYPT News

  • EyePoint up 12% premarket on expanded access of Dexycu
  • seekingalpha.2d ago
  • GPRO, CLVS among premarket gainers
  • Seeking Alpha - Article.2d ago
  • EyePoint Pharmaceuticals Announces New Agreement With Large US Delivery System To Offer DEXYCU Within Its Network
  • Benzinga.2d ago
  • EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.
  • GlobeNewswire.2d ago

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About EYPT

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
More

Webull offers Eyepoint Pharmaceuticals Inc (EYPT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.